I am not the best at financials, and if anyone wants to correct me feel free, but just out of curiosity I'd like to examine other Stem Cell companies and compare them to USRM. I took all these numbers from the most recent 10q's of each company, and most up to date info I could find. This is open for discussion, and imo a very complex situation. Let's just take a glance and ponder, but be mindful that NONE of these companies have FDA approval for their Stem Cell therapies/products... They are ALL going through Clinical Trials. Each company displays a tremendous risk/reward and unique situation. Which companies will be among some of the first to receive FDA approval for Stem Cell therapies? Could USRM become one of the first? With the recent passing of The Cures Act, will USRM be a major benefactor?
Some of the share structures from the other stem cell companies are not that different from USRM as to where they are trading in dollars and USRM is trading sub-penny with such a small market value. We can begin to make our case as to why USRM is undervalued with the advancement of the most recent clinical trials for degenerative disc disease, and the wealth of developments throughout the years since the inception of US Stem Cell Inc.
Once again I refer to this part of the most recent filing as a potential clue of what could be possible here trading this stock:
Summary: U.S. Stem Cell’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
Market Value1 $250,209 a/o Jan 27, 2017 Authorized Shares: 2,000,000,000 a/o Aug 02, 2016 Outstanding Shares: 59,573,684 a/o Nov 09, 2016 (Most Estimate 80-90million now) Current Price: $.0042 Current liabilities: $6.96M in Q3 2016 Assets: $413,316 Revenue: $729K in Q3 2016 Net loss improved: $219K in Q3 2016 Cash used in operating activities: $62k in Q3 2016 Cash at end of period: $245,991
Summary: We currently have six clinical stage programs – including a pending Phase 3 study in ischemic stroke, an ongoing Phase 2 clinical study for the treatment of damage from acute myocardial infarction, an ongoing exploratory clinical study in Acute Respiratory Distress Syndrome, and several others. We also have a portfolio of preclinical programs that we are advancing toward clinical stage development.
Current Price: $1.12 Net Loss: (6,004) Assets: $23,319.00 Current Liabilities: $23,319.00 Revenue: $150.00 (yes 150 dollars) Cash used in operating activities: (4,647) (yes that is negative $4,647.00) Cash at end of period: $8,309
3. Cytori Therapeutics, Inc. (CYTX )Nasdaq http://www.cytori.com Upcoming merger: CYTORI TO ACQUIRE AZAYA THERAPEUTICS
Summary: Cytori Therapeutics, Inc. is dedicated to enhancing lives through novel cell therapies. To realize this mission, Cytori defines, develops, and delivers specialty therapeutics that address poorly met medical needs. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, we deliver meaningful results that create exceptional value for our patients, partners, employees, shareholders, and society.
Authorized: 75 million Outstanding Shares 20,500,553 a/o Oct 31, 2016 Current Price: $1.59 Assets: $36,842,000 Current Liabilities: $23,172,000 Revenue: $731,000 Cash used in operating activities: (15,372,000) Cash at end of period: $14,924,000
Summary: Cesca has developed a complete suite of BioProcess technologies to cater to the needs of the Bio-banking, and regenerative medicine market. Our technology is designed specifically for the following groups: Clinical Development Companies (integrating GMP compliant technologies for manufacturing and storage process control) Commercialization stage companies upgrading their process to include GMP compliant... Biobanking Facilities
Authorized Share Count: 350,000,000 Outstanding Shares: 9,790,500 a/o Sep 16, 2016 Net Loss: (22,445) Current Price: $2.96 Assets: $49,185 Current Liabilities: $12,858 Revenue: $3,767 Cash used in operating activities: (2,009) Cash at end of period: $5,835
Summary: "This is an adult stem-cell company; they are going after big-ticket items like the cardiovascular space, and the data to date has shown some promise," Benjamin said. "And J&J (Johnson & Johnson (JNJ)) actually has option to potentially move forward with the company and the therapeutic if they like the next set of data that comes out, probably sometime next year." https://www.thestreet.com/story/13238523/1/four-stem-cell-stocks-with-promise.html
Market Value $48,361,783 a/o Jan 27, 2017 Authorized Shares 50,000,000 a/o Nov 12, 2014 Outstanding Shares 21,399,019 a/o Nov 11, 2016 Current Price: $2.26 Assets: $24,471,820 Current Liabilities: $6,670,268 Total Income: $746,781 Net Loss: (5,333,413) Cash at end of period: $18,020,875
Summary: Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation.
Market Value $89,122,095 a/o Jan 27, 2017 Authorized Shares Not Available Outstanding Shares 81,020,086 a/o Nov 02, 2016 Current Price: $1.10 Operating loss: (6,562) Net loss: $(6,324) Revenue: 0 Net cash used by operating activities: $(3,923) Assets: $40,209 Current Liabilities: $40,209
Summary: International Stem Cell Corporation (ISCO) is a publicly traded clinical stage biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.
Market Value $4,079,820 a/o Jan 27, 2017 Authorized Shares 120,000,000 a/o Sep 30, 2016 Outstanding Shares 3,642,696 a/o Nov 12, 2016 Current Price: $1.12 Cash on hand: $733 Operating loss: (6,562) Net loss: $414 Revenue: (1,262) Loss from operating activities (1,262) Assets: $7,540 Current Liabilities: $7,540
8. Stemline Therapeutics, Inc. (STML) http://www.stemline.com Summary: Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Current Price: $10.20 Grant revenue $299,401 Outstanding Share Count: 19,151,652 Total liabilities 9,275,544 Net loss$ (9,923,222)
Summary: Asterias is conducting a clinical study to evaluate the safety and activity of AST-OPC1 in patients with cervical spinal cord injury. AST-OPC1 consists of cells known as oligodendrocyte progenitor cells (OPCs). The purpose of the study is to evaluate the safety of AST-OPC1 administered once between 14 & 30 days after injury. Researchers will also assess the impact on patient hand & arm function.
Current Price : $4.35 Market Value $201,937,666 a/o Jan 27, 2017 Authorized Shares Not Available Outstanding Shares 46,422,452 a/o Nov 10, 2016 TOTAL ASSETS $70,303 TOTAL LIABILITIES $27,577 Total gross profit: 2,017
10. BioTime Inc. (BTX) (embriotic stem cells controversial studies with fetus stem cells)
Summary: Macular degeneration affects approximately 11 million people in the U.S. It is the leading cause of blindness in people over the age of 60. Approximately 90 percent of these patients suffer from the dry form, for which there are no FDA-approved therapies.
Summary: OncoMed Pharmaceuticals is a clinical-stage biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
Outstanding Shares: 33,758,423 Current Price: $8.02 Total assets $218,188 Total Liabilities: 221,369 Revenue: 5,279
Market Data 
Markets 
AI
